title: 2009 H1N1 influenza and experience in three critical care units.
abstract: OBJECTIVE
  We describe futures of ICU admission, demographic characteristics, treatment and outcome for critically ill patients with laboratory-confirmed and suspected infection with the H1N1 virus admitted to the three different critical care departments in Turkey.
  
  
  METHODS
  Retrospective study of critically ill patients with 2009 influenza A(H1N1) at ICU. Demographic data, symptoms, comorbid conditions, and clinical outcomes were collected using a case report form.
  
  
  RESULTS
  Critical illness occurred in 61 patients admitted to an ICU with confirmed (n=45) or probable and suspected 2009 influenza A(H1N1). Patients were young (mean, 41.5 years), were female (54%). Fifty-six patients, required mechanical ventilation (14 invasive, 27 noninvasive, 15 both) during the course of ICU. On admission, mean APACHE II score was 18.7±6.3 and median PaO(2)/FIO(2) was 127.9±70.4. 31 patients (50.8%) was die. There were no significant differences in baseline PaO(2)/FIO(2 )and ventilation strategies between survivors and nonsurvivors. Patients who survived were more likely to have NIMV use at the time of admission to the ICU.
  
  
  CONCLUSIONS
  Critical illness from 2009 influenza A(H1N1) in ICU predominantly affects young patients with little major comorbidity and had a high case-fatality rate. NIMV could be used in 2009 influenza A (H1N1) infection-related hypoxemic respiratory failure.
authors.affiliation: Selcuk University, Meram Medical Faculty, Pulmonary Diseases and Critical Care Department, 42080, Konya, Turkey. turgut-teke@hotmail.com
authors.forename: Turgut
authors.initials: T
authors.lastname: Teke
authors.forename: Ramazan
authors.initials: R
authors.lastname: Coskun
authors.forename: Murat
authors.initials: M
authors.lastname: Sungur
authors.forename: Muhammed
authors.initials: M
authors.lastname: Guven
authors.forename: Taha T
authors.initials: TT
authors.lastname: Bekci
authors.forename: Emin
authors.initials: E
authors.lastname: Maden
authors.forename: Emine
authors.initials: E
authors.lastname: Alp
authors.forename: Mehmet
authors.initials: M
authors.lastname: Doganay
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Erayman
authors.forename: Kursat
authors.initials: K
authors.lastname: Uzun
mesh_terms: D018806:APACHE; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D015897:Comorbidity; D003404:Creatinine / Q000097:blood; D004798:Enzymes / Q000097:blood; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification*; D007251:Influenza, Human / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality* / Q000503:physiopathology; D007362:Intensive Care Units / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000627:therapeutic use; D010100:Oxygen / Q000097:blood; D012121:Respiration, Artificial / Q000379:methods / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014421:Turkey
chemical_list: D000900:Anti-Bacterial Agents; D004798:Enzymes; D053139:Oseltamivir; D002097:C-Reactive Protein; D003404:Creatinine; D010100:Oxygen